Target intelligence / Profile preview

Vestigial-like family member 1 (VGLL1)

Target
VGLL1
Molecular classification
Transcriptional co-activator, Transcription factor co-regulator
01

Overview

VGLL1 (Vestigial-like family member 1) is a co-transcriptional activator that binds TEA domain-containing transcription factors (TEADs) via its conserved TONDU motif, modulating the expression of genes involved in cell proliferation, invasion, and development. In normal human tissues, VGLL1 is predominantly expressed in placental trophoblast cells, where it supports rapid proliferation and tissue invasion, characteristics also seen in cancer cells. Overexpression of VGLL1 is strongly correlated with poor patient outcomes in cancers such as breast, pancreatic, gastric, and ovarian malignancies. Mechanistically, VGLL1 promotes tumorigenesis by regulating key pathways (e.g., MAPK/PI3K signaling), modulating chromatin structure, and suppressing cell cycle inhibitors. No drugs specifically target VGLL1 yet, but inhibiting its interaction with TEADs represents a potential therapeutic avenue.

Other names
VGLL1Tondu protein
02

Mechanism of action

Inhibition of VGLL1-TEAD interaction (proposed strategy for drug development, but no drugs currently in use)

03

Biological functions

Regulation of transcriptionPromotion of cell proliferationEnhancement of cell invasionChromatin remodelingAngiogenesisDevelopmental processes (notably placental development)
04

Disease associations

Cancer (breast carcinoma, pancreatic cancer, gastric cancer, ovarian cancer, triple negative breast cancer)Placental biology (normal trophoblasts)
05

Safety considerations

Targeting VGLL1 may affect normal placental function because of its role in placental trophoblast proliferationPotential for off-target effects in tissues where VGLL1 is normally low or absent
06

Interacting drugs

None identified; no VGLL1-targeted therapies currently exist
07

Biomarkers

VGLL1 expression is a candidate biomarker for poor prognosis and aggressive cancer subtypes

Beyond the preview

Go deeper on Vestigial-like family member 1 (VGLL1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vestigial-like family member 1 (VGLL1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call